Cleaning Validation in Pharmaceutical Industry: A Complete Guide to Procedure, Protocol, MACO Calculation and Acceptance Criteria

Category: Pharmaceutical Quality Assurance | GMP | Validation

Estimated reading time: 15–18 minutes

1. Introduction

Cleaning validation is one of the most important elements of a pharmaceutical Quality Management System (QMS). Pharmaceutical manufacturing equipment is frequently used for processing different products, strengths and batches. If equipment is not cleaned effectively after manufacturing, residues of the previous product, active pharmaceutical ingredients (APIs), excipients, cleaning agents and microorganisms may remain on product-contact surfaces.

These residues can contaminate the next product manufactured using the same equipment. Such contamination may affect product quality, safety, identity, strength and purity and can potentially expose patients to unacceptable risks.

Cleaning validation provides documented scientific evidence that an approved cleaning procedure can consistently remove product residues, cleaning agents and other relevant contaminants to predetermined acceptable limits.

In pharmaceutical manufacturing, cleaning validation is particularly important in multiproduct facilities where common equipment is used for manufacturing different products. It helps prevent cross-contamination, supports GMP compliance and provides confidence that equipment is suitable for its intended use.

This article explains the complete cleaning validation process, including regulatory requirements, cleaning validation strategy, equipment selection, worst-case product selection, health-based exposure limits (HBEL), maximum allowable carryover (MACO), sampling methods, analytical methods, acceptance criteria, execution and ongoing verification.

2. What Is Cleaning Validation?

Cleaning validation is the documented evidence that an approved cleaning procedure consistently removes product residues, cleaning agents and other identified contaminants from manufacturing equipment and associated surfaces to scientifically justified acceptance limits.

It demonstrates that the cleaning process is reproducible, effective and suitable for its intended purpose.

Cleaning validation generally evaluates the removal of:

• Residues of the previously manufactured product.
• Active pharmaceutical ingredients (APIs).
• Excipients and processing aids.
• Cleaning agents and detergent residues.
• Degradation products and other relevant chemical residues.
• Microbial contamination, where applicable.
• Endotoxins, where relevant to the manufacturing process.

The objective is not to demonstrate absolute cleanliness at an infinitely low detection level. The objective is to establish and demonstrate a cleaning process that consistently achieves scientifically justified, safe and acceptable cleanliness levels.

3. Objectives of Cleaning Validation

The major objectives of cleaning validation are:

1. Prevention of cross-contamination: To prevent carryover of residues from one product to another.
2. Patient safety: To ensure that potential exposure to residues from previous products remains within acceptable limits.
3. Product quality: To protect the identity, strength, quality, purity and safety of the manufactured product.
4. GMP compliance: To demonstrate that cleaning procedures are developed, documented and controlled.
5. Cleaning process consistency: To establish that the cleaning procedure is reproducible under defined operating conditions.
6. Cleaning agent removal: To demonstrate that detergents and other cleaning materials are adequately removed.
7. Microbial control: To establish appropriate microbiological controls where contamination presents a risk.
8. Equipment suitability: To confirm that equipment is suitable for subsequent manufacturing operations.

4. Regulatory Requirements for Cleaning Validation

Cleaning validation requirements are addressed through GMP regulations and guidance documents issued by regulatory authorities and international organisations.

4.1 US FDA – 21 CFR Part 211

US FDA 21 CFR 211.67 addresses equipment cleaning and maintenance. It requires equipment and utensils to be cleaned and maintained at appropriate intervals to prevent contamination that could affect product quality.

Written cleaning procedures should describe responsibilities, cleaning schedules, cleaning methods, equipment and materials used, disassembly and reassembly requirements, protection of cleaned equipment and inspection before use.

21 CFR 211.182 also addresses equipment cleaning and maintenance records.

4.2 EU GMP – Annex 15

EU GMP Annex 15 addresses qualification and validation, including cleaning validation. It establishes the expectation that cleaning procedures should be validated to demonstrate their effectiveness in removing relevant contaminants.

Important considerations include:

• Cleaning validation protocols and reports.
• Risk-based selection of equipment and products.
• Cleaning process variables and worst-case conditions.
• Sampling methods and analytical procedures.
• Toxicological assessment of product residues.
• Cleaning agent residues.
• Microbial and endotoxin risks.
• Continued verification and change control.

4.3 PIC/S Recommendations PI 006-4

PIC/S published revised recommendations on qualification and validation under document PI 006-4 in July 2026. The revised document entered into force on 1 October 2026 and superseded the previous PI 006-3 recommendations.

PI 006-4 provides an updated framework for validation and qualification, with greater emphasis on risk-based activities, scientific justification and the manufacturer’s documented judgement.

Pharmaceutical manufacturers should assess the applicability of the revised recommendations and update their validation procedures and strategies where required.

4.4 WHO GMP Guidelines

WHO Technical Report Series No. 1019, Annex 3, provides guidance on validation of manufacturing processes and cleaning procedures. It describes the need to demonstrate that cleaning consistently removes product residues, cleaning agents and microbial contamination to acceptable levels.

WHO Technical Report Series No. 1033, Annex 2, discusses points to consider when including health-based exposure limits in cleaning validation.

4.5 Indian Revised Schedule M

The Revised Schedule M of the Drugs Rules, 1945, provides GMP requirements applicable to pharmaceutical manufacturing in India.

For API manufacturing, the cleaning validation provisions in the relevant GMP section address validation of cleaning procedures, representative product selection, residue limits and cleaning validation protocols.

Manufacturers should identify the specific Schedule M provisions applicable to their manufacturing activities and product category and maintain compliance with the currently applicable requirements.

4.6 Other Relevant Guidance

• EMA guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities.
• EMA questions and answers on implementation of risk-based prevention of cross-contamination.
• Health Canada Cleaning Validation Guide GUI-0028.
• WHO guidance on cleaning validation and HBEL implementation.

5. Types of Cleaning in Pharmaceutical Manufacturing

Cleaning activities are generally classified according to the manufacturing situation and the purpose of cleaning.

5.1 Batch-to-Batch Cleaning

Cleaning performed between batches of the same product. The cleaning frequency and procedure should be established through an approved SOP and risk assessment.

5.2 Product-to-Product Cleaning

Cleaning performed when changing from one product to another using shared manufacturing equipment. This is a major focus of cleaning validation because residues from the previous product may contaminate the subsequent product.

5.3 Campaign Cleaning

Cleaning performed at the end of a defined manufacturing campaign. The maximum campaign length and the need for intermediate cleaning should be scientifically justified, particularly where microbial growth or residue accumulation is a concern.

5.4 Manual Cleaning

Cleaning performed manually by trained operators using approved cleaning tools, detergents, water and specified cleaning instructions.

5.5 Automated Cleaning

Cleaning performed through automated systems such as Clean-in-Place (CIP) or automated washing equipment. Critical parameters such as temperature, flow, concentration, time and rinse conditions should be controlled and validated.

6. Cleaning Validation Lifecycle

Cleaning validation should be managed as a lifecycle activity rather than a one-time exercise. The lifecycle generally includes three important stages.

Stage 1 – Cleaning Process Development

• Identify the equipment and manufacturing process.
• Evaluate product and residue characteristics.
• Select suitable cleaning agents.
• Establish cleaning parameters.
• Identify difficult-to-clean locations.
• Develop the cleaning procedure.
• Establish scientifically justified residue limits.

Stage 2 – Cleaning Process Qualification

• Prepare and approve the cleaning validation protocol.
• Select representative or worst-case products.
• Perform cleaning validation studies.
• Collect swab and/or rinse samples.
• Analyse samples using suitable validated methods.
• Evaluate results against predetermined acceptance criteria.
• Prepare and approve the validation report.

Stage 3 – Continued Process Verification

• Monitor routine cleaning performance.
• Review cleaning records and analytical results.
• Trend deviations and failures.
• Evaluate changes to products, equipment and cleaning procedures.
• Perform periodic review and requalification when justified.

7. Preparation of a Cleaning Validation Master Plan

A Cleaning Validation Master Plan (CVMP) or an appropriate cleaning validation strategy should define how the cleaning validation programme will be implemented across the facility.

The plan should address:

• Scope and objectives of cleaning validation.
• Applicable manufacturing areas and equipment.
• Equipment grouping and equipment trains.
• Product grouping and worst-case product selection.
• Cleaning procedure development.
• HBEL and residue-limit strategy.
• Sampling and analytical methods.
• Acceptance criteria.
• Responsibilities of QA, QC, Production and Validation.
• Cleaning validation schedule.
• Continued verification and change management.

8. Selection of Equipment for Cleaning Validation

Equipment selection should be based on a documented assessment of contamination and carryover risks.

Product-contact equipment should normally be included in the cleaning validation programme. Non-product-contact surfaces should also be assessed where residues may migrate, become dislodged or otherwise contaminate subsequent products.

Examples of pharmaceutical equipment include:

Equipment grouping or bracketing may be used when scientifically justified. Equipment should not be grouped merely because it performs a similar function. Differences in design, surface area, material of construction, accessibility and cleaning mechanism should be evaluated.

9. Worst-Case Product Selection

When multiple products are manufactured using common equipment and the same cleaning procedure, a scientifically justified worst-case product approach may be used.

The worst-case product should be selected through a documented risk assessment considering the following factors:

• Toxicity or potency: Products with a lower acceptable exposure threshold may present greater carryover risk.
• Solubility: Poorly soluble products may be more difficult to remove.
• Cleanability: Sticky, oily, highly adherent or difficult-to-remove residues may represent a cleaning challenge.
• Stability: Residues that dry, degrade or form difficult-to-remove films may require additional consideration.
• Product formulation: Excipients and formulation characteristics may influence residue removal.
• Equipment contact: The equipment surface and design may influence the cleaning challenge.

A product that is difficult to clean is not necessarily the product with the greatest toxicological risk. Both cleaning difficulty and patient exposure risk must be assessed.

Where different products present different worst-case characteristics, more than one representative product or cleaning study may be necessary.

10. Health-Based Exposure Limits (HBEL) and Cleaning Validation

Health-Based Exposure Limits (HBELs) are toxicologically derived exposure thresholds used to assess the potential risk of cross-contamination when different medicinal products are manufactured in shared facilities.

A commonly used HBEL is the Permitted Daily Exposure (PDE).

PDE represents a substance-specific daily exposure level that is considered to be without appreciable health risk for the relevant patient population when applied using an appropriate toxicological assessment.

HBEL assessments should be performed by suitably qualified personnel with appropriate toxicological expertise.

10.1 Important Considerations for HBEL Assessment

• Pharmacological activity of the substance.
• Relevant toxicological studies.
• NOAEL or other suitable point of departure.
• Critical adverse effects.
• Relevant uncertainty and adjustment factors.
• Route of exposure and patient population.
• Available scientific data and its limitations.

HBEL values should be scientifically justified and periodically reviewed when relevant new toxicological information becomes available.

10.2 HBEL Is Not Automatically the Routine Cleaning Limit

An important distinction is that the HBEL is a health-based exposure threshold used for risk assessment. It should not automatically be adopted as the routine cleaning acceptance limit without considering the full manufacturing process, equipment train, analytical capability and cleaning process performance.

Manufacturers should establish appropriate cleaning limits and alert levels through a documented risk-based approach that provides assurance that the HBEL will not be exceeded in subsequent products.

11. Maximum Allowable Carryover (MACO) Calculation

Maximum Allowable Carryover (MACO) is the maximum quantity of residue from a previous product that may be carried over into the next product without exceeding the established acceptable exposure limit.

MACO calculations are an important part of cleaning validation because they help establish scientifically justified residue limits for shared manufacturing equipment.

11.1 PDE-Based MACO Formula

A commonly used calculation is:

MACO (mg) = PDE of previous product (mg/day) × Minimum batch size of next product (mg) ÷ Maximum daily dose of next product (mg/day)

Where:

• PDE: Permitted Daily Exposure of the previous product.
• Minimum batch size: Minimum batch quantity of the next product.
• Maximum daily dose: Maximum daily quantity of the next product administered to a patient.

Ensure that all units are consistent before performing the calculation.

11.2 Illustrative MACO Calculation

Assume the following example values:

MACO = (0.01 × 100,000,000) ÷ 500

MACO = 2,000 mg

Therefore, the calculated maximum allowable carryover for this illustrative product combination is 2,000 mg.

Important: This is an educational example, not an approved cleaning limit. Actual calculations must use the approved HBEL/PDE, justified batch and dose assumptions, relevant product-specific factors and applicable equipment-train considerations.

11.3 Surface Area-Based Acceptance Limit

Where the MACO is distributed across a defined equipment surface area, a surface residue limit may be calculated:

Surface limit (mg/cm²) = MACO (mg) ÷ Total shared product-contact surface area (cm²)

For example, if an illustrative MACO is 2,000 mg and the total relevant shared surface area is 200,000 cm²:

Surface limit = 2,000 ÷ 200,000 = 0.01 mg/cm²

The corresponding value is 10 µg/cm².

In actual applications, the calculation should account for the relevant equipment train, shared and non-shared equipment, product flow, residue distribution and the rationale for allocating limits to individual equipment items.

12. Traditional Cleaning Acceptance Criteria

Historically, some pharmaceutical companies used criteria such as:

• 10 ppm of previous product in the next product.
• Not more than 0.1% of the minimum therapeutic dose in the maximum daily dose of the next product.
• Visual cleanliness.

These criteria may be encountered in older cleaning validation procedures and historical documents. However, they should not automatically be treated as universally acceptable current limits.

Modern cleaning validation strategies should be based on toxicological evaluation, HBEL/PDE, scientific risk assessment and cleaning process capability.

Where legacy limits are retained, their continued suitability should be scientifically justified and documented.

13. Cleaning Validation Sampling Methods

Sampling is a critical part of cleaning validation. The selected sampling method should be capable of detecting and quantifying relevant residues at the established acceptance limits.

The two commonly used sampling methods are swab sampling and rinse sampling.

13.1 Swab Sampling – Direct Surface Sampling

Swab sampling is a direct sampling technique in which a suitable swab is used to collect residues from a defined equipment surface area.

The collected sample is extracted using a suitable solvent and analysed using an appropriate analytical method.

Procedure for swab sampling:

1. Identify and document the sampling location.
2. Define a suitable sampling area, commonly 25 cm² or another justified area.
3. Use an approved swab and suitable extraction solvent.
4. Wet the swab as specified in the approved procedure.
5. Swab the defined surface using a consistent pattern.
6. Place the swab into the approved sample container.
7. Extract the residue using the validated extraction procedure.
8. Analyse the sample using the approved analytical method.

Advantages:

• Direct measurement of residues from equipment surfaces.
• Suitable for targeted worst-case locations.
• Useful for evaluating difficult-to-clean areas.
• Can help identify localised residue accumulation.

Limitations:

• May not be suitable for inaccessible surfaces.
• Sampling recovery may vary by surface and material.
• Requires trained personnel.
• May not represent the entire equipment surface by itself.

13.2 Rinse Sampling – Indirect Sampling

Rinse sampling is an indirect technique in which a defined quantity of suitable rinse solvent is passed through or over equipment surfaces to collect residual contaminants.

The rinse sample is collected and analysed for the presence of product residues, cleaning agents or other relevant contaminants.

Procedure for rinse sampling:

1. Select a suitable rinse solvent.
2. Define the rinse volume and sampling procedure.
3. Ensure the rinse solvent contacts the relevant equipment surfaces.
4. Collect the rinse sample in a suitable container.
5. Record the rinse volume and relevant process details.
6. Analyse the sample using the approved analytical method.
7. Calculate the residue level based on the validated sampling approach.

Advantages:

• Useful for inaccessible internal surfaces.
• Can cover a larger equipment surface area.
• Useful for closed systems and transfer lines.

Limitations:

• May dilute residues and reduce sensitivity.
• May not detect localised residue deposits.
• Recovery depends on rinse solvent and equipment design.
• Does not necessarily represent all equipment surfaces.

13.3 Comparison of Swab and Rinse Sampling

13.4 Placebo Sampling

In some circumstances, a placebo or product-contact material may be used as an additional assessment technique. Its suitability should be scientifically justified, and it should not automatically replace direct or rinse sampling where those methods are needed to demonstrate cleaning effectiveness.

14. Selection of Sampling Locations

Sampling locations should be selected based on equipment design, product-contact surfaces and the potential for residue retention.

Typical difficult-to-clean locations include:

• Gaskets and seals.
• Equipment joints and connections.
• Hoppers and discharge points.
• Agitator blades and shafts.
• Mixing vessel corners.
• Transfer lines and hoses.
• Filters and screens.
• Compression machine feed frames.
• Product-contact valves.
• Dead legs and poorly drained areas.

A sampling location matrix should identify the equipment, sampling point, sampling method, surface area and scientific rationale for selection.

15. Recovery Studies in Cleaning Validation

Recovery studies are performed to determine the efficiency with which a sampling method can recover a known quantity of residue from a representative equipment surface.

Recovery studies are especially important for swab sampling because residue recovery can vary depending on the swab material, solvent, surface material and sampling technique.

Recovery percentage formula:

Recovery (%) = (Amount recovered ÷ Amount applied) × 100

For example:

• Amount of residue applied: 100 µg.
• Amount recovered: 80 µg.
• Recovery: 80%.

Recovery data should be scientifically evaluated and incorporated into the residue calculation where required by the validated method and approved procedure.

Recovery correction should not be applied inconsistently or used to conceal poor sampling performance.

16. Analytical Methods Used in Cleaning Validation

Analytical methods should be suitable for detecting and quantifying the target residue at the established acceptance limit.

Common analytical techniques include:

The analytical method should demonstrate appropriate specificity, sensitivity, accuracy, precision and other relevant performance characteristics for its intended use.

16.1 Limit of Detection (LOD)

LOD is the lowest quantity of an analyte that can be detected by an analytical method, although it may not necessarily be quantified with suitable accuracy and precision.

16.2 Limit of Quantification (LOQ)

LOQ is the lowest quantity of an analyte that can be quantitatively determined with suitable accuracy and precision.

The method’s LOQ should be sufficiently low to support reliable evaluation against the established cleaning acceptance limit.

17. Cleaning Validation Acceptance Criteria

Acceptance criteria should be established before the cleaning validation study begins. The criteria should be scientifically justified, measurable and linked to the identified contamination risks.

Typical acceptance criteria include:

17.1 Product Residue Limit

Product residues should not exceed the approved limit established through the documented toxicological and risk-based assessment.

17.2 Cleaning Agent Residue Limit

Cleaning agent residues should be controlled using a justified limit supported by suitable analytical methods or other appropriate evidence.

17.3 Visual Cleanliness

Equipment surfaces should be visually clean and free from visible product residues, detergent residues and other foreign matter.

Visual inspection is an important acceptance criterion, but it should not generally be the only evidence used to demonstrate cleaning effectiveness.

17.4 Microbiological Acceptance Criteria

Microbiological limits should be established based on the nature of the product, manufacturing process, equipment, storage conditions and contamination risk.

17.5 Rinse Water or Final Rinse Criteria

Where appropriate, parameters such as TOC, conductivity and pH may be used to evaluate the final rinse. These measurements should be supported by a suitable method and justified acceptance limits.

18. Cleaning Validation Protocol

A cleaning validation protocol is a pre-approved document describing how the cleaning validation study will be performed.

The protocol should contain sufficient information to ensure that the study is scientifically sound, reproducible and traceable.

18.1 Contents of a Cleaning Validation Protocol

1. Protocol title and unique identification number.
2. Objective and scope.
3. Applicable regulatory and internal references.
4. Responsibilities of concerned departments.
5. Description of manufacturing equipment.
6. Equipment identification and product-contact surface area.
7. Previous and subsequent product details.
8. Worst-case product selection rationale.
9. HBEL/PDE and residue-limit justification.
10. Cleaning procedure and SOP reference.
11. Cleaning parameters and operating ranges.
12. Dirty hold time and clean hold time.
13. Sampling locations and sampling methods.
14. Sampling recovery information.
15. Analytical methods and method sensitivity.
16. Acceptance criteria.
17. Number and rationale for cleaning validation runs.
18. Deviation management.
19. Data recording and result evaluation.
20. Approval requirements.

19. Cleaning Validation Procedure – Step-by-Step

The following is a general approach for implementing a cleaning validation study in a pharmaceutical manufacturing facility.

Step 1 – Identify the Equipment

Identify all relevant manufacturing equipment and components included in the validation scope. Document equipment details, surface materials, product-contact areas and equipment grouping rationale.

Step 2 – Identify Products and Product Combinations

Identify products manufactured using the equipment and evaluate previous-to-next product combinations. Determine which combinations present the highest carryover risk.

Step 3 – Perform Risk Assessment

Evaluate product toxicity, potency, solubility, cleanability, stability, equipment design and potential residue accumulation.

Step 4 – Select Worst-Case Product

Select the representative product or products using documented scientific justification. Consider both toxicological risk and cleaning difficulty.

Step 5 – Establish Residue Limits

Obtain or establish the appropriate HBEL/PDE and calculate relevant carryover and surface residue limits. Establish suitable limits for cleaning agents and microbiological contamination where applicable.

Step 6 – Develop the Cleaning Procedure

Define cleaning materials, detergent concentration, water quality, cleaning sequence, disassembly requirements, cleaning time, temperature, rinsing conditions and drying requirements.

Step 7 – Establish Hold Times

Determine the maximum dirty hold time between the end of manufacturing and commencement of cleaning. Establish the clean hold time between completion of cleaning and equipment use.

Step 8 – Prepare the Validation Protocol

Prepare and obtain approval of the protocol from relevant departments before executing the study.

Step 9 – Perform Cleaning Validation Runs

Execute the cleaning procedure under defined conditions. Include relevant worst-case conditions and routine operating variability in the study design.

Step 10 – Collect Samples

Collect swab and/or rinse samples according to the approved sampling plan. Record sampling locations, sample identification, sampling time and other required details.

Step 11 – Perform Laboratory Analysis

Analyse samples using approved methods. Ensure that analytical method sensitivity is suitable for the established acceptance criteria.

Step 12 – Evaluate Results

Compare the results with predefined acceptance criteria. Evaluate all relevant product residue, cleaning agent and microbiological results.

Step 13 – Investigate Deviations

Any failure, unexpected result or deviation should be investigated. The impact on the validation conclusion should be assessed and documented.

Step 14 – Prepare the Validation Report

Summarise the study, results, deviations, calculations, acceptance criteria and conclusions in a final report.

Step 15 – Approve and Implement Routine Monitoring

After successful completion and approval, implement the approved cleaning procedure and the defined continued verification programme.

20. Dirty Hold Time and Clean Hold Time

20.1 Dirty Hold Time

Dirty hold time is the maximum period that equipment may remain uncleaned after completion of manufacturing before the approved cleaning procedure is started.

Long dirty hold times may cause residues to dry, harden, adhere to equipment surfaces or become more difficult to remove. They may also increase microbiological risk in suitable environments.

Cleaning validation studies should evaluate the maximum proposed dirty hold time or other scientifically justified worst-case conditions.

20.2 Clean Hold Time

Clean hold time is the maximum approved period that cleaned equipment may be stored before being used for the next manufacturing operation.

Clean hold time studies should consider:

• Equipment storage conditions.
• Protection from environmental contamination.
• Equipment closure and covering arrangements.
• Moisture and microbial growth risks.
• Equipment design and storage location.

21. Cleaning Validation in Oral Solid Dosage Manufacturing

In oral solid dosage manufacturing, several equipment types may be used for different products. Cleaning validation should address all relevant product-contact components and difficult-to-clean locations.

22. Cleaning Validation in Liquid and Semi-Solid Manufacturing

Liquid and semi-solid manufacturing equipment may present specific cleaning challenges because of viscous products, sticky residues, transfer lines and complex vessel geometries.

Important equipment includes:

• Manufacturing vessels and mixing tanks.
• Homogenisers and agitators.
• Transfer pumps and pipelines.
• Filters and filling equipment.
• Hoses, valves and gaskets.
• Product-contact filling nozzles.

Cleaning validation should consider residue solubility, product viscosity, equipment drainage, cleaning agent compatibility and the effectiveness of rinsing.

23. Manual Cleaning and CIP Validation

23.1 Manual Cleaning

Manual cleaning depends significantly on operator technique and consistency. Therefore, cleaning procedures should clearly define:

• Equipment disassembly and reassembly.
• Cleaning tools and their approved use.
• Cleaning agent concentration.
• Water quality and temperature.
• Scrubbing technique and cleaning sequence.
• Cleaning and rinsing duration.
• Drying and equipment protection.

Operator training and practical qualification should be considered where manual cleaning performance is dependent on individual technique.

23.2 Clean-in-Place (CIP)

CIP systems clean equipment and process systems without requiring complete manual dismantling.

Critical CIP parameters may include:

• Cleaning solution concentration.
• Cleaning temperature.
• Flow rate and pressure.
• Cleaning duration.
• Rinse volume and sequence.
• Spray device coverage.
• Drainability and return flow.

Where automated cleaning is used, the relevant operating ranges, instrumentation, control systems and cleaning cycles should be qualified or validated as appropriate.

24. Cleaning Validation Report

The final cleaning validation report provides documented evidence of the study outcome and whether the cleaning procedure has met the approved requirements.

The report should include:

• Protocol number and report number.
• Objective and scope of the study.
• Equipment details and identification.
• Product and worst-case selection rationale.
• Approved cleaning procedure reference.
• Executed cleaning validation runs.
• Dirty and clean hold time information.
• Sampling locations and methods.
• Analytical method details.
• Recovery study results where applicable.
• Acceptance criteria and residue calculations.
• Analytical results and result evaluation.
• Deviations and investigations.
• Conclusion and limitations.
• Continued verification and revalidation requirements.
• Departmental review and approval.

25. Cleaning Validation Deviations and Failure Investigation

If cleaning validation results exceed established acceptance criteria, the failure should be investigated through the approved deviation and investigation system.

Potential causes include:

• Inadequate cleaning agent concentration.
• Insufficient cleaning time.
• Incorrect cleaning temperature.
• Inadequate rinsing.
• Incorrect cleaning sequence.
• Improper equipment disassembly.
• Residue accumulation in difficult-to-clean locations.
• Inadequate operator training.
• Sampling technique or recovery issues.
• Analytical method or laboratory errors.
• Equipment design or drainage problems.

The investigation should evaluate the root cause, impact on the study and any potentially affected batches or equipment status.

Corrective and preventive actions may include:

• Revision of the cleaning SOP.
• Improvement of cleaning agent concentration or contact time.
• Additional rinsing or cleaning steps.
• Improvement in equipment design or accessibility.
• Operator retraining and competency assessment.
• Dedicated equipment where justified.
• Additional validation or verification studies.

Repeated cleaning and retesting until an acceptable result is obtained should not be used to conceal an unsuccessful cleaning process. Each failure must be documented and scientifically evaluated.

26. Cleaning Validation vs Cleaning Verification

27. Continued Cleaning Process Verification

After successful cleaning validation, the cleaning process should remain under an appropriate monitoring and review programme.

Continued verification may include:

• Review of cleaning records.
• Periodic analytical monitoring based on risk.
• Review of cleaning failures and deviations.
• Monitoring of detergent concentration and cleaning parameters.
• Trend analysis of residue results.
• Review of dirty and clean hold time compliance.
• Review of operator training and competency.
• Periodic review of HBEL and residue-limit assessments.

The frequency and extent of routine analytical testing should be supported by a documented Quality Risk Management approach and applicable regulatory expectations. Any reduction in testing should be scientifically justified and approved.

28. When Is Revalidation Required?

Revalidation or a documented reassessment may be required when significant changes could affect the validated cleaning process.

Examples include:

• Introduction of a new product or formulation.
• Change in product toxicity or HBEL assessment.
• Change in cleaning agent or detergent.
• Change in cleaning procedure or critical parameters.
• Modification or replacement of manufacturing equipment.
• Change in equipment surface material.
• Change in equipment train or manufacturing process.
• Repeated cleaning failures or adverse trends.
• Change in dirty or clean hold time.
• Significant changes in water quality or cleaning utilities.

The need for revalidation should be assessed through the approved change control and quality risk management systems. Revalidation should be based on the nature and impact of the change rather than performed automatically at an arbitrary interval.

29. Roles and Responsibilities in Cleaning Validation

30. Common Cleaning Validation Audit Observations

During regulatory inspections and customer audits, cleaning validation programmes may be assessed for scientific justification, procedural control, documentation and effectiveness.

Examples of potential deficiencies include:

1. Absence of a documented cleaning validation strategy.
2. Inadequate justification for worst-case product selection.
3. Use of outdated or scientifically unsupported residue limits.
4. Failure to consider HBEL/PDE in cross-contamination risk assessment.
5. Inadequate selection of difficult-to-clean sampling locations.
6. Absence of suitable sampling recovery studies.
7. Analytical method sensitivity not suitable for the acceptance limit.
8. Inadequate evaluation of cleaning agent residues.
9. Dirty hold time and clean hold time not adequately justified.
10. Insufficient control of manual cleaning variables.
11. Inadequate evaluation of CIP critical parameters.
12. Visual inspection treated as the only evidence of cleaning effectiveness.
13. Repeated cleaning and retesting without appropriate investigation.
14. Inadequate continued verification and change management.

31. Best Practices for an Effective Cleaning Validation Programme

• Develop a scientifically justified cleaning validation strategy.
• Use qualified toxicological expertise for HBEL/PDE assessments.
• Apply Quality Risk Management principles throughout the lifecycle.
• Select worst-case products based on multiple relevant factors.
• Include difficult-to-clean equipment locations in the sampling strategy.
• Establish suitable analytical methods with adequate sensitivity.
• Conduct recovery studies where appropriate.
• Control cleaning parameters through approved SOPs.
• Qualify and train personnel involved in manual cleaning.
• Monitor automated cleaning cycles and critical process parameters.
• Maintain complete and traceable documentation.
• Trend cleaning results and investigate adverse patterns.
• Review cleaning validation after relevant changes.

32. Cleaning Validation Checklist for Pharmaceutical Industry

The following checklist can be used as a general reference while reviewing a cleaning validation programme.

33. Frequently Asked Questions (FAQs)

1. What is cleaning validation in the pharmaceutical industry?

Cleaning validation is documented evidence that an approved cleaning procedure consistently removes product residues, cleaning agents and other relevant contaminants from manufacturing equipment to predetermined acceptable limits.

2. Why is cleaning validation important?

It prevents cross-contamination, protects patient safety, maintains product quality and demonstrates compliance with pharmaceutical GMP requirements.

3. What is MACO in cleaning validation?

MACO means Maximum Allowable Carryover. It is the maximum quantity of residue from a previous product that may be carried over into the next product without exceeding the established acceptable exposure limit.

4. What is HBEL in cleaning validation?

HBEL means Health-Based Exposure Limit. It is a toxicologically derived exposure threshold used to assess the risk of cross-contamination in shared manufacturing facilities. PDE is a commonly used HBEL value.

5. What is the difference between PDE and MACO?

PDE is a health-based daily exposure threshold for a substance. MACO is a calculated maximum quantity of previous-product residue that may be carried over into a subsequent product under defined manufacturing assumptions.

6. What are the main sampling methods used in cleaning validation?

The two common methods are swab sampling, which directly collects residues from a defined surface, and rinse sampling, which collects residues through a suitable rinse solvent.

7. Is visual inspection sufficient for cleaning validation?

No. Visual inspection is an important part of cleaning assessment, but it should generally be supported by suitable analytical evidence and scientifically justified acceptance criteria.

8. What is dirty hold time?

Dirty hold time is the maximum approved time equipment may remain uncleaned after manufacturing before the cleaning process begins.

9. What is clean hold time?

Clean hold time is the maximum approved period cleaned equipment may be stored before it is used for the next manufacturing operation.

10. How many cleaning validation runs are required?

The number of runs should be justified through the approved validation strategy and applicable regulatory guidance. A fixed number should not be treated as universally mandatory without considering the current applicable requirements and scientific rationale.

11. What is the purpose of a recovery study?

A recovery study determines how effectively the selected sampling method can recover a known amount of residue from a representative equipment surface.

12. When is cleaning revalidation required?

Revalidation or documented reassessment may be required following significant changes to products, equipment, cleaning agents, cleaning procedures, critical parameters or other conditions that could affect cleaning effectiveness.

34. Conclusion

Cleaning validation is a critical GMP requirement for pharmaceutical manufacturing facilities, particularly those operating shared equipment and multiproduct manufacturing lines.

An effective cleaning validation programme should be based on scientific understanding, toxicological risk assessment, appropriate equipment selection, justified residue limits, suitable sampling methods and reliable analytical techniques.

Manufacturers should move beyond the simple use of historical cleaning limits and adopt a lifecycle-based approach that considers HBEL/PDE, cleaning process capability, equipment design, worst-case conditions and continued verification.

Ultimately, the objective of cleaning validation is to ensure that manufacturing equipment remains suitable for its intended use and that the risk of cross-contamination is appropriately controlled to protect product quality and patient safety.

References and Further Reading

1. US FDA – Guide to Inspections: Validation of Cleaning Processes
2. 21 CFR 211.67 – Equipment Cleaning and Maintenance
3. European Commission – EudraLex Volume 4, EU GMP Guidelines
4. PIC/S – Recommendations on Qualification and Validation, PI 006-4
5. WHO TRS 1019, Annex 3 – Validation
6. WHO TRS 1033, Annex 2 – Points to Consider When Including HBELs in Cleaning Validation
7. European Medicines Agency – Scientific Guidelines
8. Health Canada – Cleaning Validation Guide GUI-0028
9. Central Drugs Standard Control Organisation (CDSCO), India

About the Author

Mahummed Asif is a pharmaceutical Quality Assurance professional with extensive experience in pharmaceutical manufacturing, GMP compliance, Quality Management Systems, IPQA, validation and regulatory requirements. He shares practical pharmaceutical quality and regulatory knowledge through PharmaShare.in to support pharmaceutical professionals and students.

Disclaimer: This article is intended for educational and professional knowledge-sharing purposes. It does not replace applicable regulatory requirements, approved company procedures, product-specific toxicological assessments or qualified expert advice. Each pharmaceutical manufacturer should establish cleaning validation requirements based on its products, processes, equipment and applicable regulations.